Receptor specific transepithelial transport of therapeutics
CA 2297101 C · Owner: Brandeis University · Inventors: Blumberg, Richard S.; Simister, Neil E.; Lencer, Wayne I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates in general to methods and products for initiating an immune response against an antigen and in particular relates to , transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular the invention relates , to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium mucosal epithelium and , epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as or , in, pharmaceutical …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 1998 and granted September 13, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.